Business Wire

SAMWHA ELECTRIC, a Leading Manufacturer of Electrolytic Capacitor, Draws Attention in World Electronics Market

Share

SAMWHA ELECTRIC (KRX:009470), a specialty manufacturer of electrolytic capacitors in Korea, attracts attention in the world electronics market by launching a conductive polymer hybrid electrolytic capacitor built on advanced technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200424005097/en/

SAMWHA ELECTRIC, a specialty manufacturer of electrolytic capacitors in Korea, attracts attention in the world electronics market by launching a conductive polymer hybrid electrolytic capacitor built on advanced technology. SAMWHA ELECTRIC has been providing the global market with its electric double layer capacitor ‘Green-Cap’ used for eco-friendly high-valued products, such as 5G, eco-friendly vehicles, medical devices, LED, robots, Internet-of-Things (IoT), and energy storage systems (ESSs) for wind and solar power for many years. Thanks to a long replacement cycle based on fast charge/discharge cycles for over 1 million times, Green-Cap is easy to maintain and it can be used in extreme temperatures. As it does not contain environmentally hazardous substances, it is also easy to treat after use. (Graphic: Business Wire)

SAMWHA ELECTRIC, a specialty manufacturer of electrolytic capacitors in Korea, attracts attention in the world electronics market by launching a conductive polymer hybrid electrolytic capacitor built on advanced technology. SAMWHA ELECTRIC has been providing the global market with its electric double layer capacitor ‘Green-Cap’ used for eco-friendly high-valued products, such as 5G, eco-friendly vehicles, medical devices, LED, robots, Internet-of-Things (IoT), and energy storage systems (ESSs) for wind and solar power for many years. Thanks to a long replacement cycle based on fast charge/discharge cycles for over 1 million times, Green-Cap is easy to maintain and it can be used in extreme temperatures. As it does not contain environmentally hazardous substances, it is also easy to treat after use. (Graphic: Business Wire)

SAMWHA ELECTRIC has been providing the global market with its electric double layer capacitor ‘Green-Cap’ used for eco-friendly high-valued products, such as 5G, eco-friendly vehicles, medical devices, LED, robots, Internet-of-Things (IoT), and energy storage systems (ESSs) for wind and solar power for many years.

Thanks to a long replacement cycle based on fast charge/discharge cycles for over 1 million times, Green-Cap is easy to maintain and it can be used in extreme temperatures. As it does not contain environmentally hazardous substances, it is also easy to treat after use.

With increasing demand in strategic markets including electric vehicles, communication, smart consumer electronics, renewable energies, UPS, automotive industry and electronic components, orders for the product is growing worldwide. Through its five sales subsidiaries in Germany, the United States, China, Thailand and India as well as 14 major regional offices in other countries, the company has built stable international business infrastructure to lead the global market.

Expecting brighter future in line with expansion in eco-friendly automotive infrastructure and increase in demand for eco-friendly power due to expanded environment regulation policies, SAMWHA ELECTRIC aims to meet demands for high-specification products by developing high-valued devices at its corporate R&D center and to take an advantageous position while transforming into a leading electronic component company by developing proprietary technologies.

“In order to grow into an integrated electronic parts maker through systematic quality control, we are implementing management systems in three stages, and effectively managing production processes with enterprise resource planning (ERP), a real-time data management system, and manufacturing execution system (MES),” said a manager at SAMWHA ELECTRIC.

Backed by these efforts, SAMWHA ELECTRIC is further advancing into the global market with synergies of designation as one of beneficiaries of support program of the Korea Trade-Investment Promotion Agency (KOTRA). The company also values shared growth with affiliates by establishing partnership relations. The corporate culture of SAMWHA ELECTRIC that shares values with clients has potential for further development with their trust.

Products by SAMWHA ELECTRIC

- EDLC (Electric Double Layer Capacitor) for Radial, Snap-in, Axial Type & Module
- Conductive Polymer Hybrid Aluminum Electrolytic Capacitor for Radial, SMD Type
- Aluminum Electrolytic Capacitor for Radial, SMD, Snap-in, Lug, Screw Type

Main Application

- Household Appliance for High Ripple Current, Miniaturization and Long Life
- Solar Power Inverter for High Voltage, High Capacitance and High Ripple Current
- Power Electronics for High Capacitance, High Ripple Current and Long Life and Power Industry, Plant Business, Infrastructure Business Segment
- Led Lighting for Ultra-High Temperature, Long Life and Low Impedance
- Automotive for powertrain (ECU, DC/DC Converter), Safety (Breaking, Airbag, ABS) and Exterior (LED Headlight)

Contact information

SAMWHA Electric H.Q.
Mr. Yong Dong Kim
+82-2-2056-1646
sesale1@samwha.com

SAMWHA EUROPE GmbH
Mr. Kwang Hyun Park
+49-0-69-9637-65-0
europe@samwha.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom